Abstract Number: 0210 • ACR Convergence 2022
Themes in Patients’ Discordance with Provider’s Rheumatoid Arthritis Treatment Goals Relate to Patient Age, Gender, and Ethnicity
Background/Purpose: We previously reported on themes in patients' treatment goals and their association with rheumatoid arthritis (RA) disease activity (DA) and aspects of rheumatology care,…Abstract Number: 0255 • ACR Convergence 2022
Is Abatacept as Effective and Safe in Rheumatoid Arthritis Patients with Previous Malignancy as in Those Without?
Background/Purpose: In 2019, a study based on post-marketing surveillance data in Japan reported that abatacept (ABT) was as effective and safe in elderly patients with…Abstract Number: 0271 • ACR Convergence 2022
Temporal Trends and Risk of Rheumatoid Arthritis in Celiac Disease Patients: A Nationwide Population-based Study
Background/Purpose: There has been an increasing global prevalence of celiac diseases (CD) and rheumatoid arthritis (RA). Modifications in proteins play a significant role in the…Abstract Number: 0289 • ACR Convergence 2022
Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and was approved under Taiwan's National Health Insurance (NHI) reimbursement system in…Abstract Number: 0306 • ACR Convergence 2022
Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…Abstract Number: 0511 • ACR Convergence 2022
SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of…Abstract Number: 0582 • ACR Convergence 2022
Development of Novel Glucocorticoid as Immunology Antibody-Drug Conjugate Payload for the Treatment of Autoimmune and Inflammatory Diseases
Background/Purpose: Glucocorticoids (GCs) are widely used to treat a variety of autoimmune and inflammatory diseases like rheumatoid arthritis, inflammatory bowel disease, and asthma. The anti-inflammatory…Abstract Number: 0603 • ACR Convergence 2022
Survivin-dependent Regulation of Bivalent Chromatin and Its Relevance for Adaptive Immunity
Background/Purpose: Bivalent chromatin (BvCR) is characterized by simultaneous binding of active and repressive modifications to the histone H3 proteins. Influencing expression of the genes, BvCR…Abstract Number: 0621 • ACR Convergence 2022
Altered Immunological Circadian Rhythms and the Effect of Treatment with Glucocorticoids on Circadian Rhythms of Immune Cells in Patients with Rheumatoid Arthritis: Bring Back the Rhythm
Background/Purpose: Clinical symptoms of rheumatoid arthritis (RA), including pain, joint stiffness, and swelling, exhibit a distinct circadian rhythm that exacerbates in the early morning in…Abstract Number: 0731 • ACR Convergence 2022
Remote Monitoring of Chronic Inflammatory Musculoskeletal Diseases– Results of the Digireuma Feasibility Study
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMDs) require a tailored follow-up that is limited by the capacity of healthcare professionals. The implementation of innovative…Abstract Number: 0800 • ACR Convergence 2022
Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications
Background/Purpose: In patients with rheumatic diseases herpes zoster (HZ) has been identified as one of the most common infections associated with immunosuppression. Shingrix is a…Abstract Number: 0893 • ACR Convergence 2022
ATP-Binding Cassette G1 Membrane Transporter-mediated Cholesterol Efflux Capacity Influences Coronary Atherosclerosis and Cardiovascular Risk in RA
Background/Purpose: Cholesterol efflux capacity CEC measures the ability of high-density lipoprotein (HDL) to remove cholesterol from arterial wall macrophages upon interaction with membrane transporter proteins…Abstract Number: 0909 • ACR Convergence 2022
Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs
Background/Purpose: This study aimed to 1) Analyze the circulating inflammatory profile of Rheumatoid Arthritis (RA) patients, in order to recognize distinctive clinical phenotypes associated with…Abstract Number: 0925 • ACR Convergence 2022
Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
Background/Purpose: Chronic pain associated with rheumatoid arthritis (RA) leads to impaired patient function and quality of life. Prior studies suggest initiation of disease-modifying antirheumatic drugs…Abstract Number: 0991 • ACR Convergence 2022
Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19
Background/Purpose: To compare use of autoimmune disease treatments between patients with and without severe COVID-19 (COVID) in cohorts of patients with systemic lupus erythematosus (SLE),…
- « Previous Page
- 1
- …
- 91
- 92
- 93
- 94
- 95
- …
- 188
- Next Page »